Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Depletion of ATP Limits Membrane Excitability of Skeletal Muscle by Increasing Both ClC1-Open Probability and Membrane Conductance

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Probing Context-Dependent Modulations of Ipsilateral Premotor-Motor Connectivity in Relapsing-Remitting Multiple Sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Functional Loss After Meningitis-Evaluation of Vestibular Function in Patients With Postmeningitic Hearing Loss

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Mitochondrial Function in Gilles de la Tourette Syndrome Patients With and Without Intragenic IMMP2L Deletions

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Functional neuroimaging of recovery from motor conversion disorder: A case report

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prevalence and significance of anti-phosphatidylserine antibodies: A pooled analysis in 5992 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinical utility of anti-MOG antibody testing in a Danish cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Antiphospholipid syndrome

    Research output: Contribution to journalReviewResearchpeer-review

  • Iris-Katharina Penner
  • Eva Catharina Sivertsdotter
  • Elisabeth G Celius
  • Siegrid Fuchs
  • Karen Schreiber
  • Sara Berkö
  • Anders Svenningsson
  • TYNERGY trial investigators
View graph of relations

BACKGROUND: Fatigue is a frequent symptom in multiple sclerosis (MS) and often interrelated with depression and sleep disorders making symptomatic treatment decisions difficult. In the single-arm, observational phase IV TYNERGY study, relapsing-remitting MS patients showed a clinically meaningful decrease in fatigue over 1 year of treatment with natalizumab.

OBJECTIVE: To evaluate whether fatigue improvement might be directly linked to improved depression and day-time sleepiness.

METHODS: Patients were assessed regarding fatigue, depression, and day-time sleepiness. The relation between changes of the two latter symptoms and changes in fatigue was analyzed.

RESULTS: After 1 year of natalizumab treatment, the majority of patients (>92%) remained stable or improved in total, motor, and cognitive fatigue. Proportion of patients without depression increased by 17% while proportions of mildly depressed patients or patients with potential major depression decreased by 5 and 12%, respectively. Proportion of patients classified as not being sleepy increased by 13% while proportions of sleepy and very sleepy patients decreased by 11 and 2%, respectively. Most importantly, improved depression and sleepiness were significantly related to improved fatigue.

CONCLUSION: Our findings highlight the importance of patient-reported outcomes in identifying potential benefits of drug treatment beyond its well-established effects on disease activity and disability progression.

Original languageEnglish
JournalFrontiers in Neurology
Volume6
Pages (from-to)18
ISSN1664-2295
DOIs
Publication statusPublished - 2015

ID: 45769924